Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

被引：0
|
作者：
Ahn, Eugene R.
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Halabi, Susan
Dib, Elie G.
Haggstrom, Daniel Ernest
Alguire, Kathryn B.
Alvarez, Ricardo H.
Calfa, Carmen Julia
Cannon, Timothy Lewis
Crilley, Pamela A.
Gaba, Anu G.
Marr, Alissa S.
Sangal, Ashish
Thota, Ramya
Antonelli, Kaitlyn R.
Islam, Samiha
Rygiel, Andrew Lawrence
Bruinooge, Suanna S.
Schilsky, Richard L.
机构：
[1] Canc Treatment Ctr Amer, Zion, IL USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] Med Univ South Carolina, Charleston, SC 29425 USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Sanford Hlth, Sioux Falls, SD USA
[6] Levine Canc Inst, Charlotte, NC USA
[7] Grand Rapids Oncol Program, Grand Rapids, MI USA
[8] Canc Treatment Ctr Amer, Newnan, GA USA
[9] Mem Canc Inst, Hollywood, FL USA
[10] Inova Schar Canc Inst, Fairfax, VA USA
[11] Canc Treatment Ctr Amer, Boca Raton, FL USA
[12] Roger Maris Canc Ctr, Fargo, ND USA
[13] Univ Nebraska Med Ctr, Omaha, NE USA
[14] Canc Treatment Ctr Amer, Goodyear, AZ USA
[15] Intermt Healthcare, Murray, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9041
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
    Ahn, Eugene R.
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Dib, Elie G.
    Haggstrom, Daniel E.
    Alguire, Kathryn B.
    Calfa, Carmen J.
    Cannon, Timothy L.
    Crilley, Pamela A.
    Gaba, Anu G.
    Marr, Alissa S.
    Sangal, Ashish
    Thota, Ramya
    Antonelli, Kaitlyn R.
    Islam, Samiha
    Rygiel, Andrew L.
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    JCO PRECISION ONCOLOGY, 2020, 4 : 757 - 766
  • [2] Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Pisick, Evan P.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Liz
    Worden, Francis P.
    Bauman, Jessica R.
    Fu, Siqing
    Leidner, Rom S.
    Balmanoukian, Ani Sarkis
    Calfa, Carmen
    Carrizosa, Daniel R.
    D'Andre, Stacy D.
    Nabell, Lisle
    Park, Min S.
    Powell, Steven Francis
    Thota, Ramya
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Al Baghdadi, Tareq
    Halabi, Susan
    Garrett-Mayer, Elizabeth
    Mangat, Pam K.
    Ahn, Eugene R.
    Sahai, Vaibhav
    Alvarez, Ricardo H.
    Kim, Edward S.
    Yost, Kathleen J.
    Guo, Kuo
    Rygiel, Andrew Lawrence
    Antonelli, Kaitlyn R.
    Butler, Nicole L.
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
    Worden, Francis P.
    Pisick, Evan
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Khalil, Maged F.
    Carrizosa, Daniel R.
    Bauman, Jessica R.
    Leidner, Rom S.
    Duvivier, Herbert L.
    Fu, Siqing
    Park, Min S.
    Yost, Kathleen J.
    Calfa, Carmen J.
    Marr, Alissa S.
    Balmanoukian, Ani S.
    Behl, Deepti
    Cannon, Timothy L.
    Nabell, Lisle
    Powell, Steven Francis
    Thota, Ramya
    Hinshaw, Dominique C.
    Gregory, Abigail
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [5] Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Al Baghdadi, Tareq
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Yost, Kathleen J.
    Chiu, Vi Kien
    Duvivier, Herbert Leon
    Mckean, Meredith
    Rueter, Jens
    Taylor, Mark A.
    Grantham, Gina N.
    Gregory, Abby
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 308 - 308
  • [6] Cetuximab (C) in patients (Pts) with breast cancer (BC) and non-small cell lung cancer (NSCLC) without reported KRAS, NRAS, BRAF mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Fisher, Julie
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Mangat, Pam K.
    Alvarez, Ricardo H.
    Cannon, Timothy L.
    Crilley, Pamela
    Pollock, Theodore
    Al Baghdadi, Tareq
    Cotta, Jared A.
    Rygiel, Andrew L.
    Antonelli, Kaitlyn R.
    Islam, Samiha
    Bruinooge, Suanna S.
    Schilsky, Richard L.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Schuetze, Scott
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Liz
    Meric-Bernstam, Funda
    Farrington, Laura Catherine
    Calfa, Carmen
    D'Andre, Stacy D.
    Livingston, Michael B.
    Thota, Ramya
    Marr, Alissa S.
    von Mehren, Margaret
    Wentzel, Kristopher
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Srkalovic, Gordan
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Nazemzadeh, Reza
    Cannon, Timothy Lewis
    Duvivier, Herbert Leon
    Yost, Kathleen J.
    Pakkala, Suchita
    Alva, Ajjai Shivaram
    Behl, Deepti
    Gold, Philip Jordan
    Calfa, Carmen Julia
    Ngirailemesang, Melissa
    Powell, Steven Francis
    O'Lone, Raegan
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Behl, Deepti
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Farrington, Laura Catherine
    Crysler, Oxana V.
    Dib, Elie G.
    Duvivier, Herbert Leon
    Hall, Michael J.
    Salmon, John Stuart
    Alese, Olatunji B.
    Marr, Alissa S.
    Ngirailemesang, Isa
    Polavaram, Latha
    Thota, Ramya
    Yang, Eddy Shih-Hsin
    O'Lone, Raegan
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 122 - 122
  • [10] Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Julie G. Fisher
    David Tait
    Elizabeth Garrett-Mayer
    Susan Halabi
    Pam K. Mangat
    Julian C. Schink
    Ricardo H. Alvarez
    Dan Veljovich
    Timothy L. Cannon
    Pamela A. Crilley
    Theodore Pollock
    Carmen J. Calfa
    Tareq Al Baghdadi
    Ramya Thota
    Nicole Fleming
    Jared A. Cotta
    Andrew L. Rygiel
    Sasha L. Warren
    Richard L. Schilsky
    Targeted Oncology, 2020, 15 : 733 - 741
12345